Chiefy is a hospital and health care company that specializes in zero waste and zero harm in surgery. Chiefy makes it easy for surgeons, anesthesiologists, nurses, and other stakeholders to align on the case plan earlier through asynchronous virtual huddles. It captures lessons, notes, and feedback after procedures and drives continuous improvement. With Chiefy, quality and communication best practices are seamlessly baked into daily operations, helping teams collaborate strikingly smarter and get closer to patients. Founded by Maya Ber Lerner and Assaf Ziv in 2020, it is located in New York, New York.
Formulator is a mental healthcare platform designed to enhance the productivity and accessibility of mental health services for patients and healthcare providers. It provides a structured case formulation tool that assists individuals in articulating their situations and goals, which can then be shared with their clinicians. This approach allows for a more focused dialogue between patients and therapists, enabling healthcare professionals to address core issues effectively from the outset. By facilitating better communication and understanding, Formulator aims to optimize the care experience for both patients and providers.
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
A cloud platform empowering global expanded and managed access programs.
Quantivly provides data liquidity and analysis tools to help radiology providers make smarter decisions, increase access to medical imaging for the population, and deliver on the promise of patient-centered healthcare. It is an imaging provider of information about radiology operations.
Neuroute (neuroute.ai) is the AI-powered system for smarter clinical trials. Backed by PharmStars (Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche & Eli Lilly). Website Neuroute.ai
Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England.
We are reinventing the claims process in private health insurance (PHI). Existing claims processes suffer from significant friction in the user journey and a lack of cost control for insurers. We eliminate the friction in this process while putting effective cost controls in place. Our solution is to provide insurers with co-branded debit cards distributed to their members. Each member can use their card at any health-related facility in the world - eliminating out-of-pocket expenses entirely. Think of corporate spend management providers like Payhawk, only for international and domestic private health insurers. So, the advantages are obvious: we help insurers to provide a 10x better user experience and to achieve substantial cost savings by providing structured data, offering real-time visibility on claims costs, minimizing fraudulent claims, and implementing a reward/cashback program to steer user behavior.
MedAll is a training platform for healthcare professionals and students: a 'virtual medical school'. MedAll enables healthcare organisations to deliver and store their training courses, conferences and teaching sessions in one place - and to share that training with the healthcare community internationally.
Alfie Health is a virtual obesity management clinic, which uses its proprietary AI clinical decision support technology to recommend a combination of precision medicine and behavioural change to help patients sustainably lose weight. Alfie provides ongoing medical supervision and support via regular telehealth visits.
Cardiomatics offers cutting-edge, cloud AI-based digital analysis of ECG data. It is a medical-grade system, based on accurate algorithms, ensuring high-quality and trusted outcomes. As a digital health technology developer, Cardiomatics cooperates with physicians, manufacturers, and providers of ECG devices globally.
Text-based Health Assistant for patients. With Lena, clinics can offer callers the option to skip the long call queues and schedule their appointment via SMS-text live chat. Value-based care organizations and payers can offer members a text-based assistant that can take care of health tasks such as scheduling appointments and coordinating their care.
The Lowdown is a one-stop shop for women to choose, access and use the right contraception and reproductive healthcare for them. Powered by user-generated content, medical advice and prescriptions, they use their unique community-first approach to put women in control of their healthcare decisions. The Lowdown was founded in 2019 and is headquartered in London, England.
Promptly is a Health Data Analytics company, collecting, integrating and analyzing data on the outcomes of care. Promptly develops proprietary technology for patient engagement, real-world data collection, and outcomes analytics, discovering digital biomarkers on important symptoms, adverse effects and treatment outcomes, using different sources of data. In partnership with some of the most visionary, forward-looking healthcare organizations, the company leverages this health data to promote better healthcare at lower costs for thousands of patients every day.
EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
moveUP develops and commercialise digital therapeutics solutions. Its closed loop system enables high compliance, better outcome and satisfaction. It uses continuously collected data to directly personalise the treatment of the patient. Its first therapy treats orthopaedic patients undergoing a joint surgery. It has CE medical device & ISO 13485 certification.
contextflow revolutionizes the medical information search process with the help of deep learning: our 3D image-based search engine for radiologists looks for regions of interest within images (currently 18+ patterns in lung CTs); when a suspicious pattern is detected, we immediately find visually similar cases, descriptions and relevant reference information, affording doctors easy access to knowledge currently hidden in large medical image data and their associated reports...all within seconds. No more paging through books, guessing the right keyword or consulting various text-based reference search engines. In addition, our software can be configured to allow for prioritization of cases where patterns of interest are detected. contextflow is a spin-off of the Medical University of Vienna (MUW), Technical University of Vienna (TU) and European research project KHRESMOI. Founded by a team of AI and engineering experts in July 2016, the company was awarded the distinction of Most Promising Startup by the BCS Search Industry, received the Digital Innovation Award by the Austrian Federal Ministry of Education, Science and Research and was selected as one of 19 startups out of over 700 applications to participate in the Philips HealthWorks accelerator program. It is currently testing its 3D image-based software with six partners, expanding internationally to other locations later this year.
Replica Analytics develops unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data
BioLib is a biomedical data analysis platform. They are the first platform for zero-knowledge analysis of biological and health data. They offer scientists access to a market for modern bioinformatics and diagnostics technologies, enabling data holders and analytics specialists to work safely and conveniently.
Segmed offers extensive clinical data and diagnostic-grade medical images to support life sciences and technology industries. The company facilitates rapid discovery and development of predictive models, improving patient recruitment and data management. Its solutions cater to pharmaceutical and medical device sectors, enhancing research and regulatory processes.
PlenOptika is a company that spun out from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium. The founders were research fellows in a biomedical technology innovation initiative who felt compelled to solve the problem of low vision suffered by more than 1 billion people worldwide. Their mission is to make eye care easy for anyone who needs it in the United States, and accessible to underserved and low-resource communities worldwide. PlenOptika has been recognized by international social innovation foundations and business plan competitions. They have collaborated with research centers in the United States, Spain, and India to develop their groundbreaking technology, QuickSee.
Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow. The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant to facilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers. Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose.
Sarcura GmbH is an Austrian deep-tech startup developing an instrument platform for the industrial manufacturing of advanced cell therapies. Our platform combines silicon chip technology and microfluidic processing to enable real-time process control and manipulation on a cellular level, enabling a fully automated and modular manufacturing system..
EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
Recent advances in artificial intelligence have made it possible for computers to understand images, sound, text and make decisions, in many cases, better and faster than humans. Methinks uses these new techniques, namely, Google's new deep learning framework, Tensorflow, to analise neuroimaging for diagnosis of brain related diseases. We focus on specific pathologies, like acute stroke, to obtain clinical excellence.
Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch.
They are building world-class diagnostic aids to help cardiologists — powered by artificial intelligence. To date, they have developed the world’s most accurate echocardiography software to improve the diagnosis of coronary heart disease by more than 90%.
contextflow revolutionizes the medical information search process with the help of deep learning: our 3D image-based search engine for radiologists looks for regions of interest within images (currently 18+ patterns in lung CTs); when a suspicious pattern is detected, we immediately find visually similar cases, descriptions and relevant reference information, affording doctors easy access to knowledge currently hidden in large medical image data and their associated reports...all within seconds. No more paging through books, guessing the right keyword or consulting various text-based reference search engines. In addition, our software can be configured to allow for prioritization of cases where patterns of interest are detected. contextflow is a spin-off of the Medical University of Vienna (MUW), Technical University of Vienna (TU) and European research project KHRESMOI. Founded by a team of AI and engineering experts in July 2016, the company was awarded the distinction of Most Promising Startup by the BCS Search Industry, received the Digital Innovation Award by the Austrian Federal Ministry of Education, Science and Research and was selected as one of 19 startups out of over 700 applications to participate in the Philips HealthWorks accelerator program. It is currently testing its 3D image-based software with six partners, expanding internationally to other locations later this year.
Segmed offers extensive clinical data and diagnostic-grade medical images to support life sciences and technology industries. The company facilitates rapid discovery and development of predictive models, improving patient recruitment and data management. Its solutions cater to pharmaceutical and medical device sectors, enhancing research and regulatory processes.
Neurescue, a medical device manufacturer based in Denmark, is developing cardiovascular devices to help emergency patients. Neurescue’s first product, the safeREBOA device, is the first computer-aided aortic occlusion catheter. Our future goal is to enable the potential clinical utility of further intelligent procedures.
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
PlenOptika is a company that spun out from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium. The founders were research fellows in a biomedical technology innovation initiative who felt compelled to solve the problem of low vision suffered by more than 1 billion people worldwide. Their mission is to make eye care easy for anyone who needs it in the United States, and accessible to underserved and low-resource communities worldwide. PlenOptika has been recognized by international social innovation foundations and business plan competitions. They have collaborated with research centers in the United States, Spain, and India to develop their groundbreaking technology, QuickSee.
We bring the power of Artificial Intelligence to the long-term care sector, so that each care home can do more and do it better. We drive each care home to the future, offering technological solutions able to combine CARE NEEDS and MANAGEMENT DUTIES. Our goal is to amplify the resources of healthcare workers and managers, improving their daily work and ensuring each resident a new care model. The future of care homes begins with an A. With ANCELIA, our solution based on advanced Artificial Intelligence algorithms, we can automatically collect information on the conditions of each resident and analyze every useful data for the management control. This way: - We EMPOWER AND IMPROVE the daily assistance activities, extending the quality of care to a greater number of residents without additional effort, - We take advantage of the hidden value of data, delivering analyses and reports that OPTIMIZE DECISION MAKING AND MANAGEMENT PROCESS for each manager, amplifying your available resources. In doing so, WE GUARANTEE THE HIGHEST QUALITY OF CARE, providing a new assistance care model, based on: - personalized assistance, - objective data, - trasparency
contextflow revolutionizes the medical information search process with the help of deep learning: our 3D image-based search engine for radiologists looks for regions of interest within images (currently 18+ patterns in lung CTs); when a suspicious pattern is detected, we immediately find visually similar cases, descriptions and relevant reference information, affording doctors easy access to knowledge currently hidden in large medical image data and their associated reports...all within seconds. No more paging through books, guessing the right keyword or consulting various text-based reference search engines. In addition, our software can be configured to allow for prioritization of cases where patterns of interest are detected. contextflow is a spin-off of the Medical University of Vienna (MUW), Technical University of Vienna (TU) and European research project KHRESMOI. Founded by a team of AI and engineering experts in July 2016, the company was awarded the distinction of Most Promising Startup by the BCS Search Industry, received the Digital Innovation Award by the Austrian Federal Ministry of Education, Science and Research and was selected as one of 19 startups out of over 700 applications to participate in the Philips HealthWorks accelerator program. It is currently testing its 3D image-based software with six partners, expanding internationally to other locations later this year.
Mindpeak provides artificial intelligence solutions that automate tissue diagnostics for cancer treatment. The company focuses on enhancing the efficiency of cancer experts by streamlining tasks such as cell and biomarker quantification. These tools integrate seamlessly into existing workflows, allowing specialists to concentrate on critical decision-making processes.
At Kheiron, we are going where only a few have gone before; seeking a new understanding of cancer and how to detect it using artificial intelligence and human insight. We’ve made significant breakthroughs with our breast cancer screening product Mia but this is just the beginning of our journey. Ultimately we want to radically improve the outcomes for cancer patients by pioneering a new era of, what we call, precision radiology. While this all sounds very serious and it is, we believe in having fun along the way. Karaoke is our favourite sport. We also have an incredible crew from more than twenty different countries and offices in London, Budapest, Amsterdam and San Francisco. Giving every woman a better fighting chance against cancer.
Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes.